GRB2 (Growth factor receptor-bound protein 2) is a crucial adaptor protein involved in intracellular signal transduction, particularly within the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) signaling pathway. It plays a pivotal role in linking activated cell surface receptors, such as EGFR and insulin receptor, to downstream effector molecules by recruiting guanine nucleotide exchange factors (e.g., SOS1) via its SH3 domains. Structurally, GRB2 contains one Src homology 2 (SH2) domain flanked by two SH3 domains, enabling interactions with phosphorylated tyrosine residues on receptors and proline-rich motifs on signaling partners, respectively.
GRB2 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to detect GRB2 protein levels, assess post-translational modifications, or investigate protein-protein interactions. Dysregulation of GRB2-mediated signaling has been implicated in cancer progression, immune disorders, and metabolic diseases, making GRB2 antibodies valuable for research into therapeutic targeting. For instance, elevated GRB2 expression correlates with tumor growth and metastasis in certain cancers. Commercially available GRB2 antibodies are typically validated for specificity across human, mouse, and rat samples, with monoclonal and polyclonal variants offering flexibility for diverse experimental designs. Proper validation using knockout controls or peptide blocking is critical to ensure antibody reliability in downstream applications.